The Vetr crowd upgraded its rating for Regeneron Pharmaceuticals, Inc. REGN from 1 star (Strong Sell), issued three days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was edging cautious, with 55 percent of Vetr user ratings bearish.
May has been good to shares in the pharmaceutical company, which is up more than 17 percent over the first 18 days of the month. This is in part due to a successful earnings report, in addition to the company's affirmation on positive guidance for 2017 that promised continued revenue growth.
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for Regeneron is down at $437.82, which is still above the average analyst target price of $431.90. Less than 2 percent of Vetr users are holding REGN in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
